Compare Panacea Biotech with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs NATCO PHARMA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH NATCO PHARMA PANACEA BIOTECH/
NATCO PHARMA
 
P/E (TTM) x 12.2 15.5 78.7% View Chart
P/BV x 2.9 3.1 96.3% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 PANACEA BIOTECH   NATCO PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
NATCO PHARMA
Mar-18
PANACEA BIOTECH/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs3641,080 33.7%   
Low Rs129671 19.2%   
Sales per share (Unadj.) Rs96.8592.1 16.3%  
Earnings per share (Unadj.) Rs-12.4188.4 -6.6%  
Cash flow per share (Unadj.) Rs-2.9206.3 -1.4%  
Dividends per share (Unadj.) Rs08.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs50.4833.6 6.0%  
Shares outstanding (eoy) m61.2536.90 166.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.51.5 172.3%   
Avg P/E ratio x-19.94.6 -427.5%  
P/CF ratio (eoy) x-86.44.2 -2,036.9%  
Price / Book Value ratio x4.91.1 465.7%  
Dividend payout %04.4 0.0%   
Avg Mkt Cap Rs m15,10132,311 46.7%   
No. of employees `0002.54.8 51.1%   
Total wages/salary Rs m1,5163,256 46.6%   
Avg. sales/employee Rs Th2,401.94,522.5 53.1%   
Avg. wages/employee Rs Th614.2674.0 91.1%   
Avg. net profit/employee Rs Th-307.91,439.0 -21.4%   
INCOME DATA
Net Sales Rs m5,92821,848 27.1%  
Other income Rs m82404 20.4%   
Total revenues Rs m6,01022,252 27.0%   
Gross profit Rs m8459,284 9.1%  
Depreciation Rs m585662 88.4%   
Interest Rs m1,006154 653.1%   
Profit before tax Rs m-6648,872 -7.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m991,920 5.1%   
Profit after tax Rs m-7606,952 -10.9%  
Gross profit margin %14.342.5 33.6%  
Effective tax rate %-14.921.6 -68.7%   
Net profit margin %-12.831.8 -40.3%  
BALANCE SHEET DATA
Current assets Rs m5,60321,307 26.3%   
Current liabilities Rs m6,9105,920 116.7%   
Net working cap to sales %-22.070.4 -31.3%  
Current ratio x0.83.6 22.5%  
Inventory Days Days20673 281.0%  
Debtors Days Days84107 78.6%  
Net fixed assets Rs m9,94114,986 66.3%   
Share capital Rs m61369 16.6%   
"Free" reserves Rs m3,02630,353 10.0%   
Net worth Rs m3,08730,760 10.0%   
Long term debt Rs m5,7070-   
Total assets Rs m16,07637,151 43.3%  
Interest coverage x0.358.6 0.6%   
Debt to equity ratio x1.80-  
Sales to assets ratio x0.40.6 62.7%   
Return on assets %1.519.1 8.0%  
Return on equity %-24.622.6 -108.9%  
Return on capital %3.929.3 13.3%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,60010,322 15.5%   
Fx outflow Rs m1,1312,978 38.0%   
Net fx Rs m4697,343 6.4%   
CASH FLOW
From Operations Rs m1,1804,636 25.5%  
From Investments Rs m553-11,155 -5.0%  
From Financial Activity Rs m-1,6446,509 -25.2%  
Net Cashflow Rs m90-18 -498.3%  

Share Holding

Indian Promoters % 74.5 52.0 143.2%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 0.6 7.8 7.7%  
FIIs % 1.3 16.6 7.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 26.0 90.8%  
Shareholders   10,259 25,395 40.4%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   NOVARTIS  ASTRAZENECA PHARMA  BIOCON   IPCA LABS  JUBILANT LIFE SCIENCES  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Jumps 1,921 Points, FM's Tax Relief, and Top Cues in Focus Today(Pre-Open)

Share markets in India jumped sharply on Friday after Finance Minister Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 20, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - DR. DATSONS LABS COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS